IDXX vs. ZBH: IDEXX Laboratories vs. Zimmer Biomet Stock Comparison

Company Profile

IDEXX Laboratories (IDXX) and Zimmer Biomet (ZBH) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

IDEXX Laboratories (IDXX) has an aggressive beta of 1.44, indicating higher sensitivity to broad-market moves, while Zimmer Biomet (ZBH) is defensive at 0.42 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

IDEXX Laboratories (IDXX) at 68.93% clears its industry range for ROE, a sharper capital-efficiency signal than Zimmer Biomet (ZBH) at 6.03%, which is closer to a typical peer reading.

IDEXX Laboratories (IDXX) at 25.36% retains a top-quartile share of revenue as profit, ahead of Zimmer Biomet (ZBH) at 8.95%, which keeps about the industry-typical share.

Both IDEXX Laboratories (IDXX) at 33.14% and Zimmer Biomet (ZBH) at 17.35% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both IDEXX Laboratories (IDXX) at 10.42% and Zimmer Biomet (ZBH) at 7.20% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both IDEXX Laboratories (IDXX) at 22.59% and Zimmer Biomet (ZBH) at -19.86% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Zimmer Biomet (ZBH) at 1.46 keeps current ratio within its industry’s typical mid-range, while IDEXX Laboratories (IDXX) at 1.19 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for IDXX.

Both IDEXX Laboratories (IDXX) at 0.52 and Zimmer Biomet (ZBH) at 0.60 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

IDEXX Laboratories (IDXX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zimmer Biomet (ZBH) reports a yield of 0.90%, ranking against industry peers normally.

IDEXX Laboratories (IDXX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zimmer Biomet (ZBH) reports a payout of 24.24%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both IDEXX Laboratories (IDXX) at 45.56 and Zimmer Biomet (ZBH) at 26.66 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Zimmer Biomet (ZBH) at 2.33 prices around its industry’s typical P/S ratio, while IDEXX Laboratories (IDXX) at 11.42 clears its benchmark range — IDXX looks notably rich on sales.

Zimmer Biomet (ZBH) at 1.58 sits in the lower P/B ratio quartile relative to book while IDEXX Laboratories (IDXX) at 28.50 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics